Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 10
Submit an article Journal homepage
617
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients – a multicenter retrospective observational study

Shai Shimonya Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel;b Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7245-9652
ORCID Icon,
Moshe Yeshuruna Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel;b Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Ofir Wolacha Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel;b Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelORCID Iconhttps://orcid.org/0000-0002-8662-0707
ORCID Icon,
Ron Ramb Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;c Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
,
Uri Rozovskia Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel;b Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Liat Shargiana Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel;b Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelORCID Iconhttps://orcid.org/0000-0002-6429-148X
ORCID Icon,
Tsila Zukermand Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine – Technion, Haifa, IsraelORCID Iconhttps://orcid.org/0000-0002-6204-977X
ORCID Icon,
Odelia Amitb Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;c Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
,
Yael Bar-Onb Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;c Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
,
Baher Krayemd Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine – Technion, Haifa, Israel
,
Batya Avnie Institute of Hematology, Hadassah Medical Center and Hebrew University Faculty of Medicine, Jerusalem, Israel
,
Galit Peretzf Department of Hematology and Bone Marrow Transplantation, Soroka Medical center and Faculty of Medicine, Beer Sheva, Israel
,
Pia Raanania Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel;b Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
&
Oren Pasvolskya Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel;b Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelORCID Iconhttps://orcid.org/0000-0001-9193-0059
ORCID Icon show all
Pages 2475-2481 | Received 14 Dec 2020, Accepted 29 Mar 2021, Published online: 21 Apr 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: Cancer J Clin. 2019;69(1):7–34.
  • Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012;119(1):34–43.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Schlenk RF, Breitruck J, Benner A, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–4380.
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
  • Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335.
  • Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King. Blood. 2001;98(6):1752–1759.
  • Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735–741.
  • Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454–464.
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
  • Berger T, Rozovski U, Moshe Y, et al. Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission – a multi-center historical control study. Ann Hematol. 2019;98(12):2711–2717.
  • Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002.
  • Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201–1212.
  • Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2020;132:662.
  • US Department of Health and Human Services. Common terminology criteria for adverse events v5.0 (CTCAE) [Internet]. Princ Pract Clin Trial Med. 2017. [cited 2019 Jun 17]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
  • Battipaglia G, Ruggeri A, Massoud R, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017;123(15):2867–2874.
  • Antar A, Kharfan-Dabaja MA, Mahfouz R, et al. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15(5):298–302.
  • Battipaglia G, Massoud R, Ahmed SO, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 mutated acute myeloid leukemia: an update. Clin Lymphoma Myeloma Leuk. 2019;19(8):506–508.
  • Brunner AM, Li S, Fathi AT, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175(3):496–504.
  • Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840–851.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.